Display options
Share it on

Diabetes Spectr. 2015 Nov;28(4):283-8. doi: 10.2337/diaspect.28.4.283.

Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.

Diabetes spectrum : a publication of the American Diabetes Association

S Christopher Jones, Debra L Ryan, Valerie S W Pratt, Ali Niak, Allen D Brinker

Affiliations

  1. U.S. Food and Drug Administration Office of Pharmacovigilance and Epidemiology and Office of New Drugs, Silver Spring, MD.

PMID: 26597395 PMCID: PMC4647172 DOI: 10.2337/diaspect.28.4.283

[No abstract available.]

References

  1. Am J Dermatopathol. 2014 Jun;36(6):510-2 - PubMed
  2. Pharmacoepidemiol Drug Saf. 2008 Mar;17(3):229-39 - PubMed
  3. Polymers (Basel). 2011 Sep 1;3(3):1377-1397 - PubMed
  4. J Cutan Pathol. 2014 Jan;41(1):63-5 - PubMed
  5. Diabetes Care. 2014;37(5):1367-74 - PubMed
  6. Diabetes Technol Ther. 2011 Nov;13(11):1145-54 - PubMed

Publication Types